T-CYPHER BIO HOLDINGS LIMITED

• ⚠

  Material uncertainty over going concern

  We draw attention to note 1.4 in the financial statements which indicates that the Group and Company have insufficient funds to trade for the next 12 months without further investment. The timing of the next tranche of funding is dependent on meeting certain development milestones. These events and conditions, along with the other matters explained in note 1.4, constitute a material uncertainty that may cast significant doubt on the Group's and Company's ability to continue as going concerns.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +102.7%

  £5,858,239 → £11,874,908

• Net assets

  +90%

  £6,960,824 → £13,222,597

• Employees

  +39.1%

  23 → 32

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102 §1A

Reporting scope

Consolidated group

Auditor

James Cowper Kreston Audit

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 1.4 in the financial statements which indicates that the Group and Company have insufficient funds to trade for the next 12 months without further investment. The timing of the next tranche of funding is dependent on meeting certain development milestones. These events and conditions, along with the other matters explained in note 1.4, constitute a material uncertainty that may cast significant doubt on the Group's and Company's ability to continue as going concerns.”

Group structure

1. T-CYPHER BIO HOLDINGS LIMITED · parent
   1. T-Cypher Bio Limited 100% · England and Wales · research and development of T Cell receptor therapies

Significant events

• “On 23 June 2023, T-Cypher Bio Holdings Limited successfully completed a Series A funding round for a total of £33.25 million divided into three tranches.”
• “During the year 600,000 Ordinary shares were issued fully paid for an aggregate cash consideration of £66,000. Also during the year 10,035,882 Series A Preferred shares were issued fully paid for an aggregate cash consideration of £11,599,996.”
• “On 17 July 2024, the board approved the adoption of an Enterprise Management Incentive (EMI) share option scheme, granting options over the ordinary share capital of T-Cypher Bio Holdings Ltd to employees of its subsidiary, T-Cypher Bio Ltd.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.